This phase 2 trial located in the United States aims to assess whether a tirofiban (Aggrastat) regimen of high dose amount plus a shortened infusion durationin patients undergoing percutaneous coronary intervention is better. The outcome to be measured are events such as a heart attack, major bleeding , death or urgent additional treatment needed.
The details
Percutaneous coronary intervention is a procedure used to treat narrowed arteries of the heart. These arteries have narrowed because of buildup of substances such as fat. Usually, during a percutaneous coronary intervention procedure, drugs are given to open up blood vessels. It is suggested that tirofiban (Aggrastat) regimen of high dose amount coupled with a shortened infusion duration (the length of time the drug is administered to the patient) will give better outcomes than eptifibatide (Integrilin).
Who are they looking for?
This study is recruiting 675 participants who are scheduled to undergo percutaneous coronary intervention. Participants should not be undergoing this procedure for a heart attack, and should not have had a heart attack within two days before starting study.
How will it work
Patients will be randomly assigned to one of 3 treatment groups. Patients in the first treatment group will receive short regimen of 25 mcg/kg of tirofiban followed by 0.15 mcg/kg/min infusion during and after the procedure. Patients in the second treatment group will receive 180 mgc/kg of eptifibatide followed by 2 mcg/kg/min. Patients in the third treatment group will receive a long regimen of 25 ug/kg followed by 0.15/ug/kg/min tirofiban infusion for 12-18 hours after the procedure. Participants will be followed-up for 48 hours.
